Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease

被引:39
|
作者
Gregg, L. Parker [1 ,2 ]
Tio, Maria Clarissa [3 ]
Li, Xilong [4 ]
Adams-Huet, Beverley [4 ]
de Lemos, James A. [5 ]
Hedayati, S. Susan [1 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Div Nephrol, 5939 Harry Hines Blvd,MC 8516, Dallas, TX 75390 USA
[2] Vet Affairs North Texas Hlth Care Syst, Div Nephrol, Med Serv, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Div Biostat, Dallas, TX 75390 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dept Med, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
Chronic kidney disease; Monocyte chemoattractant protein-1; Inflammation; Death; Cardiovascular; Outcomes; Albuminuria; Biomarkers; CARDIOVASCULAR EVENTS; RISK-FACTORS; ADHESION MOLECULES; PLASMA-LEVELS; POPULATION; INFLAMMATION; EXPRESSION; CALCIFICATION; NEPHROPATHY; PREVALENCE;
D O I
10.1159/000488806
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background:Monocyte chemoattractant protein-1 (MCP-1), a marker of inflammation and monocyte recruitment to atherosclerotic plaques, is associated with cardiovascular (CV) outcomes in patients with acute coronary syndrome. Although plasma levels are elevated in chronic kidney disease (CKD), associations with reduced kidney function or outcomes in CKD have not been explored. Methods: In this population-based, probability-sampled, longitudinal cohort of 3,257 participants, including 286 (8.8%) patients with CKD, we studied the association of plasma MCP-1 with estimated glomerular filtration rate (eGFR), albuminuria, death, and intermediate and hard CV outcomes in CKD and non-CKD individuals. Cox proportional hazards regression assessed associations of baseline MCP-1 with all-cause death and atherosclerotic events. Results: MCP-1 was higher in CKD than non-CKD participants (p < 0.001), and negatively associated with eGFR (r = -0.23, p < 0.0001) but not albuminuria in CKD. MCP-1 was associated with pulse wave velocity and coronary artery calcification in non-CKD but not CKD individuals. At 13.5 years, there were 230 (7.7%) deaths and 168 (6.4%) atherosclerotic events in the non-CKD vs. 97 (34.0%) deaths and 62 (27.9%) events in the CKD group (p < 0.001 for each). MCP-1 was associated with death (hazards ratio [HR] 2.0 [1.4-2.9] per log-unit increase) and atherosclerotic events (1.7 [1.0-2.9]) in CKD individuals. The HR for death in CKD remained significant (1.6 [1.1-2.3]) after adjusting for CV risk factors. Conclusions: Although plasma MCP-1 increased with decreased eGFR, it remained an independent risk factor for death in CKD. MCP-1 did not correlate with intermediate CV outcomes, implicating pathways other than atherosclerosis in the association of MCP-1 with death in CKD. (C) 2018 S. Karger AG, Basel
引用
收藏
页码:395 / 405
页数:11
相关论文
共 50 条
  • [1] Monocyte chemoattractant protein-1 and the kidney
    Haller, Hermann
    Bertram, Anna
    Nadrowitz, Felix
    Menne, Jan
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2016, 25 (01): : 42 - 49
  • [2] Association between Plasma Monocyte Chemoattractant Protein-1 Levels and the Extent of Atherosclerotic Peripheral Artery Disease
    Satiroglu, Omer
    Uydu, Huseyin Avni
    Demir, Adem
    Bostan, Mehmet
    Atak, Mehtap
    Bozkurt, Engin
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 224 (04): : 301 - 306
  • [3] DETECTION OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN HUMAN ATHEROSCLEROTIC LESIONS BY AN ANTI-MONOCYTE CHEMOATTRACTANT PROTEIN-1 MONOCLONAL-ANTIBODY
    TAKEYA, M
    YOSHIMURA, T
    LEONARD, EJ
    TAKAHASHI, K
    HUMAN PATHOLOGY, 1993, 24 (05) : 534 - 539
  • [4] Targeting monocyte chemoattractant protein-1 signalling in disease
    Dawson, J
    Miltz, W
    Mir, AK
    Wiessner, C
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (01) : 35 - 48
  • [5] Monocyte chemoattractant protein-1 and coronary artery disease
    Ikeda, U
    Matsui, K
    Murakami, Y
    Shimada, K
    CLINICAL CARDIOLOGY, 2002, 25 (04) : 143 - 147
  • [6] Urinary monocyte chemoattractant protein-1 in renal disease
    Kim, Min Jeong
    Tam, Frederick W. K.
    CLINICA CHIMICA ACTA, 2011, 412 (23-24) : 2022 - 2030
  • [7] Associations of Plasma Pentraxin 3 and Monocyte Chemoattractant Protein-1 Concentrations with Cardiovascular Disease in Patients with Chronic Kidney Disease
    Nishi, Keiko
    Imamura, Takuroh
    Kitamura, Kazuo
    Ogawa, Tsuneo
    Fujimoto, Shouichi
    Kakitsubata, Yousuke
    Ishikawa, Tadashi
    Asada, Yujiro
    Kodama, Tatsuhiko
    RENAL FAILURE, 2011, 33 (04) : 398 - 404
  • [8] Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease
    Zheng, D
    Wolfe, M
    Cowley, BD
    Wallace, DP
    Yamaguchi, T
    Grantham, JJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (10): : 2588 - 2595
  • [9] Eotaxin and monocyte chemoattractant protein-1 in chronic eosinophilic pneumonia
    Tateno, H
    Nakamura, H
    Minematsu, N
    Amakawa, K
    Terashima, T
    Fujishima, S
    Luster, AD
    Lilly, CM
    Yamaguchi, K
    EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (05) : 962 - 968
  • [10] The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium
    Huo, YQ
    Weber, C
    Forlow, SB
    Sperandio, M
    Thatte, J
    Mack, M
    Jung, S
    Littman, DR
    Ley, K
    JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (09): : 1307 - 1314